ClinicalTrials.gg
RecruitingNCT05623982Updated Aug 27, 2026

A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

A Phase 1/2 interventional study of GNC-038 in Non-hodgkin's Lymphoma, sponsored by Sichuan Baili Pharmaceutical Co., Ltd.. Recruiting at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Sichuan Baili Pharmaceutical Co., Ltd. (part of Sichuan Biokin Pharmaceutical Co., Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 195 studies in Lymphoma, Non-Hodgkin with a site in China — 82 open to participants now, 109 under way, 14 of them phase 3. Lymphoma, Non-Hodgkin · China.

Planned enrollment
104th of 183
40 · median 58
Started
2022
with 27 others
Phase 1/2
42 of 195
27 open now
Primary completion
2026-12
later than 53 of 108 live
Registered
125th of 195
by date

Among the 195 studies in Lymphoma, Non-Hodgkin with a site in China, this one is the 104th largest by planned enrollment of the 183 interventional ones that give a count, is one of 28 that started in 2022, is one of 42 in phase 1/2, reaches primary completion later than 53 of the 108 other live ones, and was the 125th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

82 of the 195 studies in Lymphoma, Non-Hodgkin with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Lymphoma, Non-Hodgkin with a site in China, or all of them as a file.
02

Study summary

To explore the safety and preliminary efficacy of GNC-038 in patients with relapsed or refractory NHL, and to determine the MTD and RP2D of GNC-038, or the MAD and DLT

Read the detailed description

phase Ib: To explore the safety and preliminary efficacy of GNC-038 in patients with relapsed or refractory NHL, and to determine the MTD and RP2Dof GNC-038, or the MAD and DLT of GNC-038 if MTD is not reached, by intravenous infusion (IV, QW) once a week (2 weeks as a cycle) phase II To explore the efficacy of GNC-038 in patients with relapsed or refractory non-Hodgkin's lymphoma

03

Conditions studied

  • Non-hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject is capable of understanding the form, voluntarily participates, and signs the informed consent form;
  2. No gender restrictions;
  3. Age: ≥18 years and ≤75 years;
  4. Expected survival time ≥3 months;
  5. Patients with confirmed non-Hodgkin's lymphoma;
  6. Patients with non-Hodgkin's lymphoma (R/R NHL);
  7. Presence of during the screening period (lymph node lesions with any long diameter ≥1.5 cm or extranodal lesions with any long diameter >1.0 cm);
  8. performance status score ≤2;
  9. Adverse reactions from prior anti-tumor treatment have recovered to ≤Grade 1 as per 5.0 criteria;
  10. Organ function levels meet the requirements before the first dose;
  11. Female subjects of or male subjects with partners of childbearing potential must use highly effective from 7 days before the first dose until 12 weeks after treatment discontinuation. Female subjects of childbearing potential must have a negative serum/urine pregnancy test within 7 days before the first dose;
  12. The subject has the ability and willingness to comply with the study protocol-specified visits, treatment plans, laboratory tests, and other study-related procedures.

Exclusion criteria

Exclusion Criteria:

  1. Pulmonary diseases classified as ≥Grade 3 according to v5.0; patients currently diagnosed with interstitial lung disease (ILD);
  2. Active infections requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc.;
  3. Active tuberculosis;
  4. Patients with active diseases;
  5. History of other within 5 years prior to the first dose;
  6. -positive and/or HBcAb-positive with HBV-DNA levels ≥ the lower limit of detection; antibody-positive with HCV-RNA levels ≥ the lower limit of detection; antibody-positive;
  7. Poorly controlled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg);
  8. History of severe cardiovascular or cerebrovascular diseases;
  9. Patients with a history of to recombinant humanized antibodies or any of GNC-038;
  10. Pregnant or lactating women;
  11. Patients with central nervous system involvement;
  12. Major surgery within 28 days before the first dose of this study or planned major surgery during the study period;
  13. Previous organ transplantation or hematopoietic stem cell transplantation (Allo-HSCT);
  14. Autologous hematopoietic stem cell transplantation (Auto-HSCT) within 12 weeks before initiating GNC-038 treatment;
  15. Current use of therapy;
  16. Radiotherapy within 4 weeks before initiating GNC-038 treatment;
  17. Chemotherapy or small-molecule targeted therapy within 2 weeks or 5 half-lives prior to treatment;
  18. CAR-T therapy within 12 weeks before initiating GNC-038 treatment;
  19. Use of any other drug in a clinical trial within 4 weeks or 5 half-lives before the first dose of this study;
  20. Any other condition deemed unsuitable for participation in this clinical trial by the investigator.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Study treatment

    Participants receive GNC-038 as intravenous infusion for the first cycle (2 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

    Drug: GNC-038

Interventions

  • Administration by intravenous infusion

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT)

    The incidence and severity of adverse events (TEAE) during treatment were graded according to the National Cancer Institute Standard for Common Terminology for Adverse Events (NCI-CTCAE, v5.0).

    Time frame: Up to 14 days after the first dose

  2. Maximum tolerated dose (MTD) or Maximum dose (MAD)

    In the dose increment stage, the highest dose whose estimated DLT rate is closest to the target DLT rate but does not exceed the upper bound of the equivalent interval of DLT rate is selected as MTD.

    Time frame: Up to 14 days after the first dose

  3. Adverse Events during Treatment (TEAE)

    TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of GNC-038. The type, frequency and severity of TEAE will be evaluated during the treatment of GNC-038.

    Time frame: Up to approximately 24 months

  4. Recommended dose for Phase II clinical studies (RP2D)

    The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of GNC-038.

    Time frame: Up to 14 days after the first dose

Secondary outcomes

  1. disease control rate (DCR)

    Number of patients showing Complete Response (CR) or Partial Response (PR) based on RECIST for the best response. Number of patients showing Complete Response (CR, disappearance of all target lesions) or Partial Response (PR, at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter) based on RECIST Criteria Version 1.0 (assessed by CT and/or MRI) for the best response.

    Time frame: Up to approximately 24 months

  2. progression-free survival (PFS)

    The PFS is defined as the time from the participant's first dose of GNC-038 to the first date of either disease progression or death, whichever occurs first.

    Time frame: Up to approximately 24 months

  3. Adverse Events of Special Interest (AESI)

    AESI is an event of scientific and medical interest specific to the sponsor's product or research project.

    Time frame: Up to approximately 24 months

  4. Cmax

    Maximum serum concentration (Cmax) of GNC-038 will be investigated.

    Time frame: Up to approximately 24 months

  5. Tmax

    Time to maximum serum concentration (Tmax) of GNC-038 will be investigated.

    Time frame: Up to approximately 24 months

  6. AUC0-INF

    Blood concentration - Area under time line.

    Time frame: Up to approximately 24 months

  7. AUC0-T

    Blood concentration - Area under time line.

    Time frame: Up to approximately 24 months

  8. T1/2

    Blood concentration - Area under time line.

    Time frame: Up to approximately 24 months

  9. anti-drug antibody (ADA) in Ⅰa

    Frequency and titer of anti-GNC-038 antibody (ADA).

    Time frame: Up to approximately 24 months

  10. DOR (Duration of Response)

    The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first.

    Time frame: Up to approximately 24 months

Other outcomes

  1. Neutralizing antibody (Nab) in phase Ⅰb

    Incidence and titer of Nab of GNC-038 will be evaluated.

    Time frame: Up to approximately 24 months

  2. Overall survival (OS) in phaseⅠb and phase Ⅱ

    The time between the start of study medication and death.

    Time frame: Up to approximately 24 months

  3. Neutralizing antibody (Nab) in phaseⅡ

    Incidence and titer of Nab of GNC-038 will be evaluated.

    Time frame: Up to approximately 24 months

  4. anti-drug antibody (ADA) in phaseⅡ

    Frequency and titer of anti-GNC-038 antibody (ADA) will be evaluated.

    Time frame: Up to approximately 24 months

07

Study locations

3 of 3 sites recruiting
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
    Recruiting
    • Jun Zhu · Contact
    • Yuqin Song · Contact
    • Jun Zhu · Principal investigator
    • Yuqin Song · Principal investigator
  • Harbin First Hospital
    Haerbin, Heilongjing, China
    Recruiting
    • Zhiguo Wang · Contact
  • Qingdao Central Hospital
    Qingdao, Shandong, China
    Recruiting
    • Ling Wang · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Dec 2026, 51 months after the start.

Of 69 industry-sponsored phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 103. This study's planned 51 months is below that.

Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2022
First posted
Nov 21, 2022
StartActual
Sep 26, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05623982
Collaborators
SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Nov 21, 2022
Start date
Sep 26, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 27, 2026

Study contacts

Sa Xiao, PHD
Contact
xiaosa@baili-pharm.com
+86-15013238943
Jun Zhu
principal investigator · Peking University Cancer Hospital & Institute
Yuqin Song
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emfizatamab

Start the discussion